This submission relates to important proposed changes to the Patented Medicine Prices Review Board (PMPRB) guidelines published on July 15, 2021.

The Canadian Forum for Rare Disease Innovators (RAREi) input begins with a reminder about the stated rationale behind the federal government’s recent decision to delay the implementation of the Patented Medicines Regulations and its priorities in doing so, including the COVID-19 pandemic response, its new Biomanufacturing and Life Sciences Strategy and the emerging national rare disease treatment strategy. In that context, RAREi takes issues with the PMPRB’s general approach in introducing new proposed guidelines changes and specifically is concerned with the broad and significant effects of the resulting lower list prices for currently-marketed medicines and earlier compliance timelines.

RAREi wishes to stress that these proposed changes, which were unexpected and not the subject of substantive consultation beforehand, add significant uncertainty for the Canadian pharmaceutical market and make it even harder than before to attract research and medicine launches that would benefit Canadian patients, clinicians, researchers, health system and the economy.

Regulations delay as part of the COVID effort and other key federal priorities

RAREi was pleased to see the federal government recognize the need to delay its new pharmaceutical pricing regulations. As RAREi outlined in its communications and submissions related to this issue to date, if implemented, the new pricing regime will have long-standing negative effects on patients, especially those suffering from rare disorders, and put Canada at a competitive disadvantage in terms of medication launches and clinical research.

The changes to the pricing regime also need to be further considered to ensure they do not undermine the federal government’s and our collective efforts to develop a national rare disease strategy and to implement the recently announced Biomanufacturing and Life Sciences Strategy. Ultimately, federal pharmaceutical policies should improve and not curtail access to rare disease therapies and should help grow the life sciences industry to protect Canadians against pandemics and other important health challenges.

During the first year of the COVID-19 pandemic, all Canadians learned what many Canadians with rare diseases, unfortunately, have known all too well for many years – the agony of not having an effective prevention or treatment available for a potentially life-threatening disease. New therapeutics developed by RAREi members and others are already saving and improving Canadian lives, and their research programs provide early access to clinicians and patients with rare diseases. Several RAREi companies are also developing COVID therapeutics.
However, as explained further in this submission, with the new proposed changes to the pricing of grandfathered medicines and their line extensions, the PMPRB will create a new obstacle for the Canadian life sciences sector and the rare disease community.

**Overall approach of PMPRB to the proposed changes**

RAREi is extremely concerned with the PMPRB’s approach in proposing substantive changes to the guidelines. RAREi members believe it is highly inappropriate for an independent quasi-judicial government agency to develop policies contrary to government’s direction and which demonstrate a strong bias against those it is mandated to regulate fairly. The PMPRB should be focused instead on impartially executing government policy in a fair and neutral manner.

These latest changes have been sprung on all stakeholders using a false pretense that they are in response to the government’s latest delay in implementing the new Patented Medicines Regulations. However, there is no justifiable reason why any such changes are needed at this point. They appear to be a means for the PMPRB to create new medication pricing policies with no regard to stakeholder input at the same time as the federal government has deemed it prudent to allow the industry to focus on addressing the COVID-19 pandemic.

Further, these changes go beyond the PMPRB’s mandate under the Patent Act. Based on the Federal Court of Appeal’s decision in the Alexion case, the PMPRB’s regulatory mandate is to ensure that prices are not excessive as a function of abuse of patent monopoly. The PMPRB offers no rationale regarding how the proposed guidelines changes will achieve this mandate or, more fundamentally, how on-market public (list) prices currently above the median of the comparator countries are excessively priced as a function of patent abuse. The fact that above-median list price medicines are marketed in Canada, and in almost every case subject to value-enhancing product listing agreements and patient support programs, demonstrates that these prices are not excessive. Affordability-enhancing mechanisms also include, among others, private sector risk pooling initiatives and the pan-Canadian Pharmaceutical Alliance’s negotiation process.

Regarding the timing, the proposed changes have been presented without warning in a mid-summer consultation period that overlaps with the federal election campaign, during which government agencies should refrain from engaging on policy changes.

Finally, section 96(5) of the Patent Act requires the PMPRB to consult with stakeholders on guidelines changes, including the pharmaceutical industry. Presenting new substantive changes with virtually no explanation, justification or impact assessment does not amount to appropriate consultation. No information session or webinars were held by the PMPRB to address the proposed changes. Stakeholder engagement in the limited time before the federal election was triggered was limited to a inadequate consultation document mainly comprised of the changes to the text in the guidelines along with a short “Frequently Asked Questions” document. Stakeholders are left to decipher the meaning of the changes and their implications.

---

It is particularly troubling that this approach was taken so soon following the publication of the PMPRB’s February 2021 communications plan,² revealing the agency’s strong negative biases against the regulated sector and other stakeholders.

Based on the above, there are very strong grounds for the government to initiate a comprehensive review of the operations of the PMPRB – including its leadership, governance, engagement approach and decision-making processes – as it is not acting in accordance with its mandate and the standards required of government agencies, the stated policy directions of the government, or in the best interests of all its stakeholders.

**Impact of lowering maximum list price for grandfathered and line extension medicines**

The PMPRB is proposing to change the key criterion for the maximum list price (MLP) for grandfathered and line extension medicines from the *highest international price* (HIP) among the PMPRB11 to the *median international price* (MIP) among the PMPRB7, as of the June 30, 2021 reporting period. This represents a significant departure from any of the previous proposals put forward by the PMPRB and undermines the extensive analyses and planning that patentees have undertaken to prepare for the impact of the impending changes on their currently marketed products.

The PMPRB’s “Frequently Asked Question” document forecasts that this change will reduce the list prices of grandfathered medicines *on average* by 10% and those for rare diseases more specifically by 3.5%, but the basis for these estimates is completely unsubstantiated. More importantly, the impact will be more drastic than this for many rare disease medicines, depending on the comparator countries used to set the maximum prices and where they are in their lifecycle. While the MIP test may have a lesser impact at the time of introduction, the further along a product is in its lifecycle the greater the potential for disparity among International prices. For this reason, the current PMPRB guidelines rely on the HIP to confirm ongoing compliance and non-excessive pricing for “existing patented drugs”, not the MIP. An analysis that considers specific classes and medicines would have been appropriate for the PMPRB to share with stakeholders.

In certain cases, reducing the maximum permitted list price could result in companies having to withdraw medicines from the Canadian market if the price is no longer viable and/or affect pricing in other markets. This would be to the great detriment of Canadian patients, particularly those with rare diseases for whom treatment options are often limited to one potential medication.

Given the above, the proposed PMPRB changes run counter to the government’s stated policy of – and strong financial commitment towards – developing a national rare disease treatment strategy for Canada. The goal of that plan is to ensure greater, more timely and more equitable access to rare disease treatments by Canadians.³

---

Earlier compliance date

When the proposed changes to the *Patented Medicines Regulations* were adopted in 2019 and new guidelines subsequently issued, patentees were given one year to comply with the changes to the pricing of grandfathered medicines. When the regulations were previously delayed, the PMPRB proposed cutting the compliance period to six months. In the face of significant pushback given the COVID pandemic context, this was subsequently changed back to one year.

With the new guidelines changes, the PMPRB is once again proposing to reduce the compliance period from one year to six months following the coming into force of the new regulations on January 1, 2022. This means that companies will have to comply with the changes by July 1, 2022.

Given the additional proposed changes to the guidelines and the ongoing pandemic, which was the primary reason for the regulations delay, it would be more appropriate to give companies more rather than less time to be compliant.

Increased uncertainty and destabilization of the Canadian market for rare disease developers

Overall, the proposed guidelines changes add to the climate of uncertainty and instability that has affected the whole life sciences sector – and the rare diseases medicines community as a whole – since pricing reforms were first proposed in 2016.

These changes and the unwillingness of the PMPRB to consult constructively or respond to the valid concerns of stakeholders have led to a serious destabilization of the Canadian market for pharmaceuticals, which are a crucial part of the Canadian health care system.

Concluding remarks

The PMPRB risks disrupting the provision of much-needed treatments for Canadians by bringing forward unpredictable, uncertain and subjective new rules and conducting insufficient consultations. The proposal also directly contradicts the federal government’s goal of ensuring the life sciences ecosystem focuses on managing the greatest health crisis to face Canada in a century, the COVID-19 pandemic, for which the key solution has been the rapid development and provision of vaccines and therapeutics developed by the global life sciences industry, including RAREi members.

In this context, RAREi recommends that the changes to the *Patented Medicines Regulations* and the guidelines be paused permanently to enable the federal government, the life sciences industry and other stakeholders to work constructively to develop better policy approaches that enhance the research and access environment for rare disease medicines.

Ultimately, RAREi believes that issues of accessibility and affordability can be resolved through innovative negotiated solutions and as part of the federal government’s national rare disease treatment strategy and in collaboration with the provinces.
About RAREi

The Canadian Forum for Rare Disease Innovators (RAREi) is a group of the Canadian operations of global biopharmaceutical companies with a specific focus on researching, developing and commercializing treatments for rare diseases.


RAREi’s vision is to shape the Canadian health system and policy environment to facilitate patient access to diagnostics and medicines that improve the lives of Canadians with rare disorders. Its objective is to affect positive policy change in the rare disease environment within the Canadian health care system to improve the health of Canadians with rare disorders and improve patient access to orphan medicines.